Literature DB >> 12556647

The ALLHAT report: a case of information and misinformation.

Michael A Weber1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12556647      PMCID： PMC8099274          DOI： 10.1111/j.1524-6175.2003.02287.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  8 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 2.  Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.

Authors:  C D Furberg; B M Psaty; M Pahor; M H Alderman
Journal:  Ann Intern Med       Date:  2001-12-18       Impact factor: 25.391

3.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

Authors:  B Neal; S MacMahon; N Chapman
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

4.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

6.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

7.  Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman; B M Massie; E D Freis; M S Kochar; R J Hamburger; C Fye; R Lakshman; J Gottdiener
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

8.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321
  8 in total
  8 in total

1.  [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors].

Authors:  J Scholze; Th Unger
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

2.  A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Michael A Weber; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

3.  Varenicline: quantifying the risk.

Authors:  Robert P Blankfield
Journal:  CMAJ       Date:  2011-09-06       Impact factor: 8.262

4.  Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Authors:  Barry R Davis; John B Kostis; Lara M Simpson; Henry R Black; William C Cushman; Paula T Einhorn; Michael A Farber; Charles E Ford; Daniel Levy; Barry M Massie; Shah Nawaz
Journal:  Circulation       Date:  2008-11-10       Impact factor: 29.690

Review 5.  Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics.

Authors:  Paolo Palatini
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-02       Impact factor: 3.738

6.  Here we go again.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

7.  Pathophysiological mechanisms should be taken into account and guide the treatment of essential arterial hypertension.

Authors:  Roberto Spoladore; Francesco Maranta; Gabriele Fragasso
Journal:  Indian Heart J       Date:  2017-01-12

8.  The JNC 7 report: challenges and dilemmas in writing guidelines.

Authors:  M A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.